In mismatch repair deficient recurrent endometrial cancer eligible for single agent PD-1 inhibitor, do you prefer pembrolizumab or dostarlimab and why?  

From KEYNOTE-158, single agent Pembrolizumab (anti-PD1) in dMMR recurrent endometrial cancer patients (N=79), ORR 48% (14% CR and 34% PR). Median PFS was 13.1 months. In this study, adverse events happened in 76% of patients. 12% had G3-4 toxicity. 7% discontinued for toxicities. 7% had G3-4 immunot...